Nanobody-Based Bioconjugates as Potent and Broadly Active Inhibitors of HIV Entry.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Nanobody-Based Bioconjugates as Potent and Broadly Active Inhibitors of HIV Entry.
- Published In:
- Journal of the American Chemical Society, 148(5), 5793-5806 (2026)
- Authors:
- Saha, Shubhra Jyoti, Kumariya, Rashmi, Davis, Phoenix A, Tourtellott, Emily, Doria-Rose, Nicole, Bewley, Carole A, Cheloha, Ross W
- Database ID:
- RPEP-16037
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16037APA
Saha, Shubhra Jyoti; Kumariya, Rashmi; Davis, Phoenix A; Tourtellott, Emily; Doria-Rose, Nicole; Bewley, Carole A; Cheloha, Ross W. (2026). Nanobody-Based Bioconjugates as Potent and Broadly Active Inhibitors of HIV Entry.. Journal of the American Chemical Society, 148(5), 5793-5806. https://doi.org/10.1021/jacs.5c22670
MLA
Saha, Shubhra Jyoti, et al. "Nanobody-Based Bioconjugates as Potent and Broadly Active Inhibitors of HIV Entry.." Journal of the American Chemical Society, 2026. https://doi.org/10.1021/jacs.5c22670
RethinkPeptides
RethinkPeptides Research Database. "Nanobody-Based Bioconjugates as Potent and Broadly Active In..." RPEP-16037. Retrieved from https://rethinkpeptides.com/research/saha-2026-nanobodybased-bioconjugates-as-potent
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.